Friday, December 31, 2021 1:16:31 AM
$BCLI recent development
1. FDA Authorizes Further NurOwn Dosing Under EAP.
2. FDA approved BrainStorm to manufacture NurOwn for the EAP at the Catalent facility.
3. Positive peer reviewed publication of NurOwn's Phase 3 Study for ALS.
4. Accelerating Access to Critical Therapies for ALS Act approved and signed.
5. Zacks Small Cap Research increased $BCLI valuation to $14.
1. FDA Authorizes Further NurOwn Dosing Under EAP.
2. FDA approved BrainStorm to manufacture NurOwn for the EAP at the Catalent facility.
3. Positive peer reviewed publication of NurOwn's Phase 3 Study for ALS.
4. Accelerating Access to Critical Therapies for ALS Act approved and signed.
5. Zacks Small Cap Research increased $BCLI valuation to $14.
Recent BCLI News
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/09/2025 07:20:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2025 09:03:10 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/03/2025 08:31:22 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/25/2025 08:39:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/25/2025 08:31:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 08:30:51 PM
- Micro-Cap Biotech Spikes After Revealing Strong ALS Survival Outcomes • AllPennyStocks.com • 06/16/2025 05:27:00 PM
